Medicinova (MNOV) Net Margin (2012 - 2026)

Medicinova (MNOV) posted quarterly Net Margin of 1841.01% for Q4 2025, up 29.37% quarter-over-quarter from 2606.72% in Q3 2025.

Medicinova (MNOV) Net Margin (2012 - 2026) Analysis & Trends

Medicinova (MNOV) has reported Net Margin for 5 consecutive years, with 1841.01% the latest figure, recorded in Q4 2025.

In Q4 2025, Net Margin changed N/A year-over-year to 1841.01%; the TTM figure through Dec 2025 stood at 3142.14% (changed N/A YoY), while the FY2025 annual figure was 2312.58%, changed N/A from the prior year.
Net Margin climbed to 1841.01% in Q4 2025 per MNOV's latest filing, from 2606.72% in the prior quarter.
Across five years, Net Margin topped out at 5.66% in Q1 2021 and bottomed at 12464.77% in Q3 2021.
Historically, Net Margin has averaged 3291.35% across 3 years, with a median of 2223.86% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Medicinova	66.94 Mn	66.94 Mn	317,759.00	-503.72%

Download Data